Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug

By PA Marks, R. Breslow. Nature Biotechnology, 2007

1,191 citations recorded by the source corpus.

Subfields: Immunology, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/803e640a186016ea658ed661a354f7de4ec36fb3

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. Steve Horvath
2. E. Seto
3. PA Marks
4. Xiang-Jiao Yang

In Molecular Biology

1. W-S Xu
2. PA Marks
3. Xiang-Jiao Yang
4. E. Seto
5. Rusty L. Montgomery
6. M. Haberland
7. Weisheng Xu
8. E. Olson

Citations in the corpus

• Epigenetic Predictor of Age (2011, background): “Furthermore, these findings could pave the way for interventions based on specific epigenetic marks associated with disease, as is already the case in cancer treatment [20].”
• The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men (2008, background): “Finally, HDAC inhibitors have great potential for treating cancer and other disease”
• Histone Deacetylase Inhibitors: Overview and Perspectives (2007, background): “Vorinostat (SAHA) is the first of the new HDACi to be approved by the Food and Drug Administration for clinical use in cancer patients for the treatment of cutaneous T-cell lymphoma.”
• Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes (2011, background): “Small-molecule HDAC inhibitors were discovered by their ability to induce redifferentiation of transformed cell”
• Histone deacetylase inhibitors: molecular mechanisms of action (2007, background): “The property of vorinostat to induce differentiation of transformed cells was discovered before identifying its inhibitory activity against HDACs (Marks and Breslow, 2007).”
• Histone Deacetylase Inhibitors: Potential in Cancer Therapy (2009, background): “T D V P B IT P R V P P S E M J S JOURNAL OF CELLULAR BIOCHEMISTRY HISTONE DEACETYLASE INHIBITORS 603 (suberoylanilide hydroxamic acid, SAHA) is the first HDACi approved for cancer therapy-advanced cutaneous T-cell lymphoma [Marks and Breslow, 2007].”
• The many roles of histone deacetylases in development and physiology: implications for disease and therapy (2009, background): “The exact mechanism for the effect of HDAC inhibitors on tumour cells is currently unknown, and numerous explanations, such as changes in gene transcription, direct induction of apoptosis, production of reactive oxygen species and induction of cell-cycle arrest, have been propose”
• HDAC family: What are the cancer relevant targets? (2009, background): “Vorinostat (SAHA) was the first HDAC inhibitor to be approved by the US Food and Drug Administration for cutaneous T-cell lymphoma in 2006 [3].”